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Abstract 
A simple mathematical equation has been developed to predict drug flux through microporated skin.  
The theoretical model is based on an approach applied previously to water evaporation through leaf 
stomata. Pore density, pore radius and drug molecular weight are key model parameters.  The 
predictions of the model were compared with results derived from a simple, intuitive method using 
porated area alone to estimate the flux enhancement.  It is shown that the new approach predicts 
significantly higher fluxes than the intuitive analysis, with transport being proportional to the total 
pore perimeter rather than area as intuitively anticipated. Predicted fluxes were in good general 
agreement with experimental data on drug delivery from the literature, and were quantitatively 
closer to the measured values than those derived from the intuitive, area-based approach.  
 
Keywords: percutaneous penetration, microporation, skin flux enhancement, mathematical 
modelling, transdermal drug delivery 
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Graphical Abstract 
 
Introduction 
The skin and its outer layer, the stratum corneum (SC), in particular, is a formidable barrier to the 
passive delivery of topical and transdermal drugs.  The ideal physicochemical characteristics for 
‘good’ skin penetrants are well-known: small molecular weight (MW), reasonable, but not 
excessive lipophilicity (log P = 2-3), adequate solubility in both oil and water, low melting point[1].  
However, these criteria are seldom satisfied and, in essence, this has meant that the most successful 
drugs that are delivered into or through the skin for therapeutic effect are those with high 
pharmacological potency [2, 3]. 
The aim to deliver drugs requiring higher doses, or those with MW > 500 (e.g., peptides and small 
proteins), has led to a substantial effort to enhance percutaneous absorption, and to reversibly 
undermine skin barrier function, using a variety of different approaches [4].  Most recently, 
attention has focused on several so-called microporation techniques, based on the use of 
microneedles, laser poration and heat ablation to create entirely new pathways across the SC and 
circumvent thereby the major resistance to passive diffusion into the viable skin tissue [5, 6]. 
The underlying principle here is that (for example) large molecules will never transport through 
intact skin at a rate necessary to be useful therapeutically and it is therefore necessary to by-pass the 
SC.  The microporation approaches do so by creating pores of 20-200 μm in diameter and of a 
depth that they are minimally invasive (i.e., as sensation-free as possible) [7, 8].  The strategy is 
reversible as the skin very effectively ‘seals’ itself quite quickly following such a disruption [9]. 
A key question when contemplating the application of a microporation technique to enhance 
topical/transdermal drug delivery is “how many pores, and of what dimension, are required to 
achieve the desired flux”?  The simple, intuitive approach to make such a prediction is to assume 
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that the flux achieved will equal that through an aqueous domain, the surface area of which equals 
that of the total pore area created (and to assume that any contribution via intact SC is negligible).  
However, this logical assumption has not undergone rigorous testing and the possibility that the 
enhancement required may be achievable with fewer pores than intuitively expected (and hence 
rendering the approach even less invasive to the patient) has not been explored.  In this paper, 
therefore, a model, based on water evaporation via leaf stomata [10, 11], for drug flux across the 
skin via micropores is developed and is compared both to the predictions from an intuitive, area-
based model and to experimental measurements in the literature. 
 
Model development 
Following a poration event, it is assumed that round pores (of radius rp), which completely 
penetrate the SC, are formed. It is further assumed that these pores are spaced at regular intervals as 
shown in Fig 1A, so that the pore density np (dimension: 1/cm2 or pore number per cm2) results in 
the spacing between the neighbouring pores of 1p pl n= .  The applied drug concentration in the 
vehicle is maintained constant (Cv) over a distance hv above the SC, while that at a depth hs below 
the SC is assumed to be zero (i.e., sink conditions) as a result, for example, of clearance by the 
dermal microcirculation (see Fig 1B).  
The steady state flux in the case that all of the SC barrier is removed may be expressed as: 
where Dv and Ds are the drug’s diffusivities in the vehicle and viable skin, respectively, and Ks is 
the partition coefficient of the drug between the viable skin and the vehicle. In the absence of SC, 
therefore, the diffusional resistance (Rno SC) to drug absorption is given by:  
     v sno SC
v s s
h hR
D K D
= +          Eq 2 
1
v s
no SC v
v s s
h hJ C
D K D
−
 
= + 
 
 Eq 1 
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When the SC is only partially removed, an analytical solution to the diffusion equation cannot be 
obtained even for the steady state and an approach similar to that developed by Patlak [11] is 
therefore used to approximate the resistance in Eq. 1 by the integral:    
Here ( )K x  and ( )D x  are step functions describing drug partitioning and diffusion in the vehicle    (
( ) 1, ( ) vK x D x D= = ) and skin ( ( ) , ( )s sK x K D x D= = ). Assuming that the SC pores are filled with 
the vehicle, then the partition and diffusion coefficients therein are the same as those in the vehicle (
( ) 1, ( ) vK x D x D= = ). Further, in Eq 3, ( )a x  is the fraction of the total area available for diffusion 
in the direction x; ( )a x  is estimated by assuming that diffusion in the layers adjacent to the pores is 
limited to the region formed by the shaded “funnels” (see Fig 1B).  
In terms of the geometry of these funnels, Patlak [11] has shown that tan 4a π≈ . When the edges 
of neighbouring funnels intercept, as determined by the coordinates sc fx h h= +  and fx h= −  on the 
skin and vehicle sides of the pore, respectively, and  
( )12 / tanf p ph l r a= − ( )2 / 8p pl rπ= −   for sc fx h h≥ +  or fx h≤ − , 
the available area of diffusion approximately equals the total area, and therefore ( )a x  = 1.  
Inside the pores ( 0 scx h≤ ≤ ) the fractional area available for diffusion is 
2( ) p pa x n rπ=  while, 
( ) ( ) ( )
sc s
v
h h
h
dxR
K x D x a x
+
−
= ∫  Eq 3 
 
Fig 1. Schematic representation of pores in SC plane (A) and side view (B) with 
relevant dimensions defined in the text. 
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inside the funnels, 2( ) ( )p fa x n r xπ= , where ( ) 4( )f p scr x r x h π= + −  for the skin side and 
( ) 4f pr x r x π= −  for the vehicle side. Thus, in summary, the functions ( )K x , ( )D x  and ( )a x  are 
given by:  
Substituting Eq 4 for ,  and  into the integral Eq 3 yields: 
With the assumption that both hv and hs are greater than or equal to hf, integration of Eq 5 produces:  
where ( )u x  is the unit step function ( ( ) 1u x =  if 0x ≥ , and ( ) 0u x =  if 0x < ). Given that 
1p pl n=  and ( )2 / 8f p ph l rπ= − , the transport resistance R depends on parameters related to the 
drug, its vehicle and the skin (Dv, Ds and Ks), the pore density and radius (np and rp), and the 
different layer thicknesses (hv, hs and hsc).  
While Eq 6 can be directly used to predict flux, for many practical cases of SC poration, further 
simplification is possible. First, it is reasonable to expect that the pore radius is much less than the 
distance between the pores ( 2 p pr l ). Second, if the pore density is not large, such that 
( )1 4 p p s vn r h h+ , it follows that: 
( )K x ( )D x ( )a x
( )
( )
2
2
2
1, for , for   
( ) ; ( )
, for  , for    
1, for 
4 , for 0
, for  0( )
4( ) , for  
1, for  
v sc v v sc
s sc s sc
v f
p p f
p p sc
p p sc sc f sc
f sc
h x h D h x h
K x D x
K x h D x h
h x h
n r x h x
n r x ha x
n r x h h x h h
x h h
π π
π
π π
− ≤ ≤ − ≤ ≤ 
= = > > 
− ≤ ≤ −

− − < ≤

< ≤= 

+ − < ≤ +
 > +
 Eq 4 
( ) ( )
0
2 22
04 4( )
f sc fsc sc s
v f sc sc f
h h hh h h
v v p p s sh h h h hv p p s s p p sc
dx dx dx dx dxR
D D n r K DD n r x K D n r x hππ π π π
− + +
− − +
= + + + +
− + −
∫ ∫ ∫ ∫ ∫
 
Eq 5 
2
21 1( ) ( )
4
v f s f p psc
v f s f
v s s v p p v s s p p p
h h h h l rhR u h h u h h
D K D D n r D K D n l rπ
− − − 
= − + − + + + 
 
 Eq 6 
( )
1
4p p s v
n
r h h+
  Eq 7 
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Hence, if the pore radius is comparable to the distance between the pores ( p pr l ), or the pore 
density is equal to or greater than the right-hand side of Eq 7, then the first two terms in Eq 6 
dominate the resistance which then approaches that in Eq 2, i.e., no SCR .  If, however, 2 p pr l  and 
Eq 7 is satisfied, then the first two terms in Eq 6 can be neglected and:  
Eq 8 is a valid approximation as long as R is significantly greater than no SCR  (defined in Eq 2). The 
reciprocal of the resistance in Eq 8 is, of course, the drug’s permeability coefficient across the 
porated skin:  
where Daq is the drug’s aqueous diffusion coefficient. It is interesting to note that kp and therefore 
the flux through compromised skin is proportional to rp (providing that p scr h≥ ) and not 
2
pr , as 
would have been expected for the intuitive model in which transport is proportional to the total area 
of pores.  In the latter case, the permeability through porated SC would equal that across skin with 
no functional barrier multiplied by the fractional pore area (Apore/Atotal): 
Eq 10 is derived from Eq 2 for noSCR  and 
2
pore total p pA A n rπ= . Note that Eq 10 (but with vh  replaced 
with v sch h+ ) can also be obtained by using 
2( ) p pa x n rπ=  in the integral Eq 3 for all values of x . 
The flux proportionality to rp rather than 2pr  for thin porated membranes is well-known and explains 
why water evaporation from a leaf is so high (about half of that expected from a fully exposed 
surface), even though the open surface area of the stomata of plant leaves is only about 1% of the 
total leaf area [11]. 
 
Eq 9 can be further simplified by assuming that Dv ~ Daq, which can be deduced from the Wilke–
Chang relationship [12]: 
41 1 11
4
sc
v p s s p p
hR
D r K D n rπ
  
= + +      
 Eq 8 
1
41 4 1 aq aqscp aq p p
p v s s
D Dhk D n r
R r D K Dπ
−
  
= = + +      
 Eq 9 
1
2
 int
1 pore aq aq
p aq p p v s
noSC total v s s
A D D
k D n r h h
R A D K D
π
−
 
= = + 
 
 Eq 10 
 7 
where MWw is the molecular weight of water (18 Da), T is the absolute temperature (305K or 32oC 
on the skin surface), ηw is the water viscosity (0.77 cP at 305K) and V is the molar volume of the 
drug at its boiling point (in cm3mole-1). In the calculations below, V is replaced by the drug’s MW 
(i.e., a density of 1 g cm-3 is assumed) and Eq 11 reduces to:  
 
The viable skin has been likened to an aqueous gel and it has been suggested that drug diffusivity 
here is about one-sixth of that in water [13]; it has therefore been assumed that ( ) 6aq s sD K D ≈ . Eq 
9 can now be simplified accordingly: if (as is the case experimentally) a typical pore diameter is 
between 10 and 200 µm, and assuming an SC thickness of 15 µm, then the term in parenthesis in Eq 
9 has a value somewhere between 7 and 10.  Using 8 as a reasonable compromise given the number 
of estimates already made, and calculating Daq with Eq 12 (having converted to units of cm2 h-1), 
the model predicts the following expressions for the permeability coefficient (in cm h-1) and the flux 
of the drug through porated skin:    
 
0.60.36p v p p vJ k C n r MW C
−= ≈  Eq 14 
 
Using the same approximations, the corresponding expressions for the intuitive model are: 
Ultimately, these permeability coefficients can be compared with the approximation of that through 
skin which has no SC whatsoever, i.e.:   
In Eqs 13-16, the units for pr , sh  and vh are cm and, for pn , cm
-2.  
( )8 2 10.6
2.6
7.4 10 wv aq
w
MW T
D D cm s
Vη
− −≈ ≈ ×  Eq 11 
( )4 0.6 2 12.0 10v aqD D MW cm s− − −≈ ≈ ×  Eq 12 
0.60.36p p pk n r MW
−≈  Eq 13 
2 0.6 2 0.6
 int int
2.3 2.3;
6 6p p p p p vs v s v
k n r MW J n r MW C
h h h h
− −≈ =
+ +
 Eq 15 
1
0.61 0.72
6
aq
noSC aq v s
noSC s s s v
D
k D h h MW
R K D h h
−
− = = + ≈  + 
 Eq 16 
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Results and discussion 
By way of illustration, Figure 2 compares the predicted skin permeability coefficients for an 
example small drug (MW = 300 and log P = 2) using the new and intuitive (area-based) models 
(Eqs 13 and 15, respectively) as 
a function of both the number 
of pores (np) and of the 
fractional pore area 
(Apore/Atotal); the calculations 
have assumed values of 
25 mpr m=  and hs = hv = 300 
µm.  The limiting permeability 
coefficient values of fully intact 
SC, determined using the Potts 
& Guy equation [14], and of 
skin with no SC whatsoever (
noSCk , Eq 16) are also included 
in the Figure. The value of hs 
was chosen on the basis of the 
situation in vivo, and the known 
ultrastructure and organisation 
of the dermal microcirculation 
[15].  The thickness of the 
dermis is on the order of 1 mm 
and, while the capillary loops in 
the dermal papillae (right beneath the epidermal-dermal junction) may not be expected to fully clear 
all drug arriving from the epidermis, the rich plexus of blood vessels situated a few hundred 
microns further down [15] is a reasonable location where ‘sink’ conditions may be expected. In 
vitro, the value of hs depends on the type of skin used (dermatomed versus full-thickness) and is 
typically 500-1000 µm as there is no functional microcirculation in this case.  In the final 
approximation of the model (Eqs 12 and 13), the principal contribution to the diffusional resistance 
is from inside the funnels, and any increase in resistance due to a larger hs is assumed negligible. 
 
Fig 2. Predicted permeability coefficients of a model 
small drug as a function of the number of pores (np) 
based on both the new model described in this work 
(solid line), and an estimate based on an intuitive, area-
based calculation (dashed line).  Horizontal lines show 
the limiting cases of the permeability coefficients for fully 
intact (kSC) and fully compromised SC (knoSC). 
k p
(c
m
/h
)
0 1000 2000 3000 4000
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10-3
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It is immediately apparent from Figure 2 that the new approach predicts a permeability coefficient 
that is approximately an order of magnitude greater than the intuitive estimate. Also, for the same 
model drug, the new model predicts that the porated skin presents no functional barrier (i.e., 
p noSCk k≥ ) once about 8% of the SC is ablated (equivalent to about 4000 pores per cm
2, in this 
case). Of course, the situation where kp > kno SC is physically impossible, as the permeability of 
porated skin can only approach that of the skin with all the SC removed. This violation is due to the 
pore density exceeding that required by Eq 7 (the right hand side is about 2000 pores per cm2), and 
indicates the limit of applicability of the new model.  
To assess the validity of the new model, it was used to predict published experimental results [16-
21] for a variety of drugs permeating across mammalian skin that had been fully porated either 
using microneedles or by laser ablation; the measured values were also compared to estimates from 
the intuitive model and the results are presented in Tables 1 and 2.  For laser-porated skin, the pore 
diameter was reported; in the case of microneedle poration, the pore radius (rp) was calculated from 
geometric considerations:   
where dn is the diameter of the microneedle base, lin is the length of that part of the microneedle 
inserted into the skin, and ln is the total microneedle length (Figure 3). It has been reported that the 
depth of the conduits created by microneedles is 40-80 μm [17] and it was therefore assumed, in the 
predictions summarized in Tables 1 and 2, that lin could be reasonably approximated to a value of 
50 µm.   
 
 
Fig 3. Geometric parameters associated with insertion of a single microneedle into the 
skin. 
2
n in
p
n
d lr
l
=  Eq 18 
l in
 
rp 
dn 
β 
l n Stratum corneum 
Epidermis 
Dermis 
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The experimental results in Tables 1 and 2 are, in general, better predicted by the new model than 
the intuitive, area-based approach.  This is illustrated graphically in Figure 4 which (for both 
microneedle and laser poration) shows the ratio of predicted to experimental fluxes for a wide range 
of drugs.  In the case of the new model (red bars), the ratio mostly falls within a factor of 5 of unity 
(i.e., 0.2 < ratio < 5) whereas, for the intuitive estimation (blue bars), the ratio is nearly always less 
than 0.2.  It follows that the novel model described in this research provides a closer description of 
the measured fluxes of drugs of diverse physicochemical properties across porated skin.  The 
approach may be valuable, therefore, in drug selection and in the design and optimisation of 
formulation strategies for transdermal delivery through selectively compromised skin. 
Figure 4 shows that the new model accurately predicts the experimentally observed fluxes for many 
compounds across microneedle-porated skin based on logical and readily available parameters, such 
as the permeant’s molecular weight, its concentration in the applied formulation, and the density 
and radius of the pores. Earlier publications have indicated that a chemical’s flux through 
microneedle-porated skin depends on the length [16], tip radius (sharpness) [22], base width [16], 
duration of application [23] and insertion force of microneedles [24]. Given the model derived here, 
these parameters are those which most directly influence the average radius of the created pores. 
Flux predictions based on Equation 14 are particularly good for the peptides and proteins (carnitine, 
hexapeptide, Ac-hexapeptide, oxytocin, cytochrome C, and BSA) that have been investigated 
experimentally.  Equally, good agreement is seen for two conventional, small molecular weight 
drugs, namely acyclovir and lidocaine. In contrast, the predictions for insulin, diclofenac, rhGH and 
FSH deviated by a factor of 5 or more from the measured values; in fact, for the latter three 
compounds, the intuitive model was a better predictor.  While the lack of agreement for insulin may 
be, at least in part, due to the animal model used (rat abdominal skin), the exact reason(s) behind 
these examples of poor prediction remain, for now, unclear. 
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Fig. 4. Ratio of predicted to experimental fluxes using the new model described here (red 
bars) and the intuitive, area-based approach (blue bars). Data are provided in Tables 1 
and 2.  
Microneedles 
Laser 
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Conclusion 
A new, relatively straightforward model has been developed to predict drug permeability through 
microporated mammalian skin.  The approach suggests that drug flux is greater through the 
compromised barrier than that indicated by a simple, intuitive, area-based model.  The validity of 
the new description was demonstrated by the generally excellent agreement between the model’s 
predictions and published experimental data; in contrast, the intuitive estimates almost always 
under-estimated (by at least a factor of 5) the measured results.  Overall, the new model provides 
additional insight into the initial conception and development of transdermal delivery approaches 
across a deliberately and quantitatively deranged skin barrier. 
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Table 1: Experimental and predicted fluxes of various drugs through microneedle-porated skin 
 
 
Drug (MW, 
Da) Skin 
hs 
(µm) 
Cv 
(µg 
mL-1) 
np   
(cm-2)  
dn 
(µm
) 
ln 
(µm) 
rp 
(µm)a 
Jexpt                 
(µg 
cm-2 
h-1) 
Jintuitive        
(µg 
cm-2  
h-1) 
Jmodel               
(µg 
cm-2 
h-1) 
Ref. 
Acyclovir 
(225) 
Human 
epidermal 
membrane 
200 1600 
2000 92 400 5.8 3.4 0.63 25.7 
[16] 
400 250 650 9.6 3.7 0.35 8.59 
900 167 650 6.4 4.5 0.35 12.9 
2000 112 650 4.3 5.0 0.35 19.2 
400 306 850 9.0 3.9 0.30 8.04 
2000 124 850 3.7 3.7 0.25 16.3 
400 250 1100 5.7 10.7 0.12 5.08 
900 167 1100 3.8 6.9 0.12 7.63 
L-Carnitine 
(161) 
Porcine 
ear, split-
thickness 
800 
14508 
756 100 150 16.7 
314 ± 
34 6.5 312 
[17] 
Hexa-peptide 
(499) 
44874 410 ± 
41 9.9 490 
Acetyl-hexa-
peptide-3 
(889) 
80010 391 ± 
124 12.9 617 
Tetrapeptide-
3 (457) 
41094 419± 
54 10.2 473 
Oxytocin    
(1007) 
90648 161 ± 
50 13.6 649 
Insulinb 
(5960) 
Rat 
abdomen, 
full-
thickness 
1500 
200 
484 100 150 16.7 
1.8 ± 
0.4 
0.004 0.32 
[18] 
350 5.6 ± 
0.4 
0.006 0.55 
740 6.3 ± 
1.0 
0.013 1.17 
920 7.0 ± 
3.1 
0.017 1.45 
 
a Pore radius calculated using Eq 18.  b FITC-labelled insulin; experimental flux determined from amount 
penetrated in 3 hours.  
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Table 2: Experimental and predicted fluxes of various drugs through laser-porated skin. 
 
Drug (MW, 
Da) 
Skin 
hs 
(µm) 
Cv (µg 
mL-1) 
np   
(cm-2) 
rp 
(µm) 
Jexpt                 
(µg cm-2  
h-1) 
Jintuitive        
(µg cm-2 
h-1) 
Jmodel        
(µg cm-2 
h-1) 
Ref. 
Lidocaine 
(234) 
Porcine ear, 
full-
thickness 
1500 
10000 
50 
75 
32 ± 4.6 2.63 51.1 
[19] 
100 58 ± 18 5.27 102 
150 69 ± 18 7.90 153 
300 75 ± 27 15.6 306 
25000 150 167 ± 58 19.8 383 
Human, 
full-
thickness 
10000 300 111 ± 8.7 15.7 306 
Diclofenac 
(296) 
Porcine ear, 
full-
thickness 
10000 
50 6.4 ± 4.4 2.29 44.4 
[20] 
100 13 ± 4.4 4.58 88.8 
150 16 ± 6.1 6.86 133 
300 22 ± 3.3 13.7 266 
Cytochrome Ca 
(12400) 
1000 
300 2.0 ± 0.37 0.15 2.83 
[21] 
100 0.47 ± 0.10 0.049 0.95 
150 0.64 ± 0.49 0.073 1.42 
600 2.1 ± 0.66 0.29 5.67 
5000 300 12 ± 1.4 0.73 14.2 
rhGHb (22000) 3300 300 0.34 ± 0.18 0.34 6.69 
FSHc (30000) 
25 
300 
0.008 ± 
0.004 
0.002 0.04 
165 1.7 ± 0.02 0.014 0.28 
330 0.09 ± 0.03 0.028 0.55 
666 0.19 ± 0.02 0.057 1.11 
BSAd (70000) 10000 300 
11.4 ± 1.3 0.52 10.0 
14.8 ± 3.7 0.52 10.0 
14.0 ± 4.6 0.52 10.0 
Cytochrome Ca 
(12400) 
Human, 
full-
thickness 
1000 300 
2.0 ± 0.78 0.15 2.83 
1.6 ± 0.34 0.15 2.83 
 
a Equine heart cytochrome C.  b Recombinant human growth hormone.  c Urinary follicle stimulating 
hormone.  d FITC-labelled bovine serum albumin. 
 
